Transamerica Financial Advisors Inc. Lowers Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Transamerica Financial Advisors Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 16,845 shares of the biopharmaceutical company’s stock after selling 235 shares during the period. Transamerica Financial Advisors Inc.’s holdings in Gilead Sciences were worth $1,413,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of GILD. Kennedy Capital Management LLC purchased a new stake in shares of Gilead Sciences in the first quarter valued at $2,946,000. B. Riley Wealth Advisors Inc. grew its holdings in Gilead Sciences by 2.2% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 28,519 shares of the biopharmaceutical company’s stock valued at $2,137,000 after buying an additional 604 shares during the period. Comerica Bank increased its stake in shares of Gilead Sciences by 0.7% during the 1st quarter. Comerica Bank now owns 332,394 shares of the biopharmaceutical company’s stock valued at $24,348,000 after acquiring an additional 2,404 shares during the last quarter. Beacon Capital Management LLC lifted its holdings in shares of Gilead Sciences by 59.9% during the 1st quarter. Beacon Capital Management LLC now owns 996 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 373 shares during the period. Finally, iA Global Asset Management Inc. boosted its position in shares of Gilead Sciences by 4.8% in the first quarter. iA Global Asset Management Inc. now owns 180,641 shares of the biopharmaceutical company’s stock worth $13,232,000 after acquiring an additional 8,350 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $91.35 on Wednesday. The company has a market capitalization of $113.85 billion, a price-to-earnings ratio of 1,015.00, a price-to-earnings-growth ratio of 2.81 and a beta of 0.17. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The business has a 50 day simple moving average of $87.74 and a 200-day simple moving average of $77.31. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.37%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Analyst Ratings Changes

GILD has been the topic of a number of recent analyst reports. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. BMO Capital Markets lifted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Mizuho upped their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Finally, Robert W. Baird lifted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,947 shares of company stock worth $4,968,674 in the last 90 days. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.